Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
135 Results for "
Neurite
" in MedChemExpress (MCE) Product Catalog:
Products (135)
135 Results for "Neurite" in MCE Product Catalog:
Cat. No.: HY-169900
CAS No.: 1842427-90-0
Research Areas:
FX 2149 is a blood-brain barrier-permeable LRRK2 inhibitor. FX 2149 inhibits the GTP-binding activity of LRRK2, reduces the kinase activity of LRRK2, and attenuates LPS (HY-D1056)-induced upregulation of LRRK2. FX 2149 alleviates mutant LRRK2-induced neurodegeneration, microglial activation, static aggregation of mitochondria and lysosomes, reduces apoptosis, and improves mitochondrial and lysosomal motility deficits in neurites. FX 2149 can be used in research related to Parkinson's disease .
Cat. No.: HY-P11777
CAS No.: 170655-66-0
Research Areas:
Cat. No.: HY-P76573
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: RGMB; Repulsive Guidance Molecule Family Member B; Repulsive Guidance Molecule BMP Co-Receptor B; Repulsive Guidance Molecule B; DRAGON; RGM Domain Family, Member B; DRG11-Responsive Axonal Guidance And Outgrowth Of Neurite; FLJ90406
Species:
Human
Source:
HEK293
Cat. No.: HY-P77178
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: RGMB; Repulsive Guidance Molecule Family Member B; Repulsive Guidance Molecule BMP Co-Receptor B; Repulsive Guidance Molecule B; DRAGON; RGM Domain Family, Member B; DRG11-Responsive Axonal Guidance And Outgrowth Of Neurite; FLJ90406
Species:
Mouse
Source:
HEK293
Cat. No.: HY-D3480
Cat. No.: HY-183405
CAS No.: 143984-56-9
Target:
Research Areas:
CD2019 is a selective retinoic acid receptor β (RARβ) agonist, with a Kd value of 26 nM for RARβ and an AC50 value of 3.8 nM for human RARβ. CD2019 regulates downstream biological effects via the PI3K signaling pathway. CD2019 suppresses squamous metaplasia, inhibits squamous differentiation markers, maintains pseudostratified epithelial structure, induces neurite and axon growth, and promotes functional recovery; it exhibits cytotoxicity at higher concentrations and reduces endogenous retinol levels. CD2019 can be used in studies related to squamous metaplasia, spinal cord injury and embryonic malformations .
Cat. No.: HY-187892
CAS No.: 3060541-19-4
Synonyms: ATH-1105
Target:
Research Areas:
Brelgometon (ATH-1105) is an orally active HGF/MET positive modulator . Brelgometon activates downstream ERK and AKT cascades. Brelgometon reduces pro-inflammatory cytokine levels and extranuclear TDP-43 aggregation; it also upregulates EAAT2 expression and improves mitochondrial function. Brelgometon protects neurons from excitotoxicity, inflammation, oxidative stress and mitochondrial dysfunction; it also maintains neurite length, neuromuscular junction integrity and sciatic nerve function. Brelgometon alleviates motor function deterioration, maintains body weight and prolongs survival in ALS transgenic mice. Brelgometon is applicable to research related to amyotrophic lateral sclerosis .
Cat. No.: HY-110155R
CAS No.: 1243259-19-9
Research Areas:
LM11A-31 dihydrochloride (Standard) is the analytical standard of LM11A-31 (dihydrochloride) (HY-110155). This product is intended for research and analytical applications. LM11A-31 dihydrochloride, a non-peptide p75NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist. LM11A-31 dihydrochloride is an amino acid derivative with high blood-brain barrier permeability and blocks p75-mediated cell death. LM11A-31 dihydrochloride reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression .
Cat. No.: HY-P82028
Synonyms: PTN; HBNF1; NEGF1; Pleiotrophin; PTN; Heparin-binding brain mitogen; HBBM; Heparin-binding growth factor 8; HBGF-8; Heparin-binding growth-associated molecule; HB-GAM; Heparin-binding Neurite outgrowth-promoting factor 1; HBNF-1; Osteoblast-specific factor 1; OSF-1
Cat. No.: HY-N21802
CAS No.: 1922084-93-2
Cat. No.: HY-P82028A
Synonyms: PTN; HBNF1; NEGF1; Pleiotrophin; PTN; Heparin-binding brain mitogen; HBBM; Heparin-binding growth factor 8; HBGF-8; Heparin-binding growth-associated molecule; HB-GAM; Heparin-binding Neurite outgrowth-promoting factor 1; HBNF-1; Osteoblast-specific factor 1; OSF-1
Cat. No.: HY-P71085
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: SERPINE2; Serpin E2; Prev. PI7; PI-7; PN1; PN-1; GDN; Serine (Or Cysteine) Proteinase Inhibitor, Clade E (Nexin, Plasminogen Activator Inhibitor Type 1), Member 2; PNI; Glial-Derived Neurite Promoting Factor; Serpin Peptidase Inhibitor, Clade E (Nexin, Pl
Species:
Human
Source:
HEK293
Cat. No.: HY-P71294
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: SERPINE2; Serpin E2; Prev. PI7; PI-7; PN1; PN-1; GDN; Serine (Or Cysteine) Proteinase Inhibitor, Clade E (Nexin, Plasminogen Activator Inhibitor Type 1), Member 2; PNI; Glial-Derived Neurite Promoting Factor; Serpin Peptidase Inhibitor, Clade E (Nexin, Pl
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P701180
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PPM1H; Protein Phosphatase 1H (PP2C Domain Containing); Prev. ARHCL1; Protein Phosphatase 1H; KIAA1157; FLJ13253; NERPP-2C; URCC2; Neurite Extension-Related Protein Phosphatase Related To PP2C; Protein Phosphatase, Mg2+/Mn2+ Dependent, 1H; Protein Phospha
Species:
Human
Source:
HEK293
Research Areas:
PD 174265 is a highly selective, reversible EGFR/ErbB2 tyrosine kinase inhibitor (IC50=0.45 nM) and cell differentiation inducer. By blocking receptor autophosphorylation and the downstream ERK signaling pathway (with an IC50 of 0.45 μM for full-length ERK), PD 174265 effectively inhibits tumor growth and exhibits antitumor activity without obvious toxicity in in vivo models. PD 174265 drives oligodendrocyte precursor cells to switch from a proliferative state to a differentiated state, significantly upregulates the expression of myelin proteins such as CNP, PLP and MBP, and induces neurite branching. PD 174265 shows no inhibitory effect on other kinases including insulin, PDGF and basic FGF receptors, and serves as a crucial tool molecule for investigating the treatment of human epidermoid carcinoma and the mechanism of myelin repair in multiple sclerosis .
Target:
Research Areas:
NCI-65828 (N-65828) sodium is a cell-permeable small molecule inhibitor. NCI-65828 inhibits the ribonuclease activity of human angiogenin and zebrafish Rnasel-1/3, as well as the activity of Mycobacterium tuberculosis AccD5 and its holoenzyme complex. NCI-65828 induces neuronal developmental defects, impairs vascular development, inhibits neurite outgrowth, and reduces protein synthesis in stem cells and neural progenitor cells, but shows no significant growth inhibitory effect on various human tumor cell lines. NCI-65828 is primarily used to study the role of angiogenin-like ribonucleases in neural and vascular development, to establish effect models of ALS-related angiogenin mutants, and in research related to amyotrophic lateral sclerosis, frontotemporal dementia, and tuberculosis .
Cat. No.: HY-182788
CAS No.: 3113741-59-3
Target:
Research Areas:
Multitarget AD-IN-7 is an orally active multi-target anti-AD compound. Multitarget AD-IN-7 exhibits inhibitory activity against GSK-3β and GSK-3α (IC50 = 0.66, 0.83 nM). Multitarget AD-IN-7 upregulates the expression of p-GSK-3β-Ser9, inhibits the phosphorylation of tau-Ser396, targets Aβ1-42, chelates pathogenic metal ions, scavenges ABTS•+, upregulates the expression of β-catenin and neurogenesis biomarkers, and promotes neurite outgrowth. Multitarget AD-IN-7 improves motor ability in Alzheimer's disease zebrafish. Multitarget AD-IN-7 is applicable to research related to Alzheimer's disease .
Cat. No.: HY-B0426A
CAS No.: 140462-76-6
Synonyms: ALO4943A; KW4679
Target:
Research Areas:
Infection Neurological Disease Metabolic Disease Inflammation/Immunology
Olopatadine hydrochloride (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine hydrochloride exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine hydrochloride inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine hydrochloride also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine hydrochloride inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine hydrochloride simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine hydrochloride can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
Target:
Potassium Channel Cholinesterase (ChE) TRP Channel NOD-like Receptor (NLR) Amyloid-β Tau Protein JNK NF-κB IKK
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology
Drofenine (Cycloadiphene; Hexahydroadiphenine) is an brain-penetrant antispasmodic agent. Drofenine is a Kv2.1 channel inhibitor with human IC50 of 9.53 μM. Drofenine is a butyrylcholinesterase (BChE) inhibitor with Ki of 0.003 mM, and is a TRPV3 activator. Drofenine blocks Kv2.1-dependent potassium efflux, inhibits Kv2.1/JNK/NF-κB and IkBa/NF-kB signaling, suppresses Kv2.1 mRNA/protein expression. Drofenine suppresses oligomeric Aβ-induced microglial NLRP3 inflammasome activation and neuronal Tau hyperphosphorylation, improves cognitive impairment, promotes neurite outgrowth. Drofenine induces calcium influx in keratinocytes and exert cytotoxicity against keratinocytes. Drofenine ameliorates diabetic peripheral neuropathy -like pathology. Drofenine can be used for the researches of Alzheimer's disease, diabetic peripheral neuropathy and smooth muscle spasm .
Cat. No.: HY-W062109
CAS No.: 113806-05-6
Target:
Research Areas:
Olopatadine (ALO4943A; KW4679) is an orally active histamine H1 receptor antagonist and mast cell stabilizer. Olopatadine exerts antiallergic effects by blocking histamine H1 receptor-mediated activities. Olopatadine inhibits exocytosis, chemokine release, F-actin polymerization, CXCL10-induced calcium influx, and T cell chemotactic activity. Olopatadine also reduces the expression levels of CXCR3 on the surface of CD4 + and CD8 + T cells. Olopatadine inhibits scratching behavior, improves dermatitis scores, and suppresses intraepidermal neurite outgrowth. Olopatadine simultaneously decreases the levels of inflammatory markers, growth factors, histamine, and specific IgE, while increasing the expression of ErbB3A/HER3A. Olopatadine can be used in research related to seasonal pollinosis, chronic rhinitis, urticaria, allergic conjunctivitis, alopecia areata, and atopic dermatitis .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
